Entakapon

Entakapon
Klinički podaci
Prodajno ime	Comtan, Comtess
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	0,4-0,7 h
Identifikatori
CAS broj	130929-57-6
ATC kod	N04BX02 (WHO)
PubChem	CID 5281081
DrugBank	DB00494
ChemSpider	4444537
KEGG	C07943
ChEBI	CHEBI:4798
ChEMBL	CHEMBL953
Hemijski podaci
Formula	C14H15N3O5
Molarna masa	305,286
	SMILES CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N; ;
	InChI InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+ ; Key:JRURYQJSLYLRLN-BJMVGYQFSA-N ;

Entakapon je organsko jedinjenje, koje sadrži 14 atoma ugljenika i ima molekulsku masu od 305,286 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	6
Broj donora vodonika	2
Broj rotacionih veza	5
Particioni koeficijent^[9] (ALogP)	1,7
Rastvorljivost^[10] (logS, log(mol/L))	-3,3
Polarna površina^[11] (PSA, Å²)	130,4

Reference

^ Najib J: Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. Najib, J. (2001 Jun). „Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease”. Clinical Therapeutics. 23 (6): 802—32. PMID 11440283. doi:10.1016/s0149-2918(01)80071-0. Проверите вредност парамет(а)ра за датум: |date= (помоћ); discussion 771.
^ Chong BS, Mersfelder TL: Entacapone. Chong, Barbara S.; Mersfelder, Tracey L. (2000 Sep). „Entacapone”. Ann Pharmacother. 34 (9): 1056—65. PMID 10981253. doi:10.1345/aph.19328. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Poewe, W. H.; Deuschl, G.; Gordin, A.; Kultalahti, E.-R.; Leinonen, M. (2002 Apr). „Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)”. Acta Neurol Scand. 105 (4): 245—55. PMID 11939936. doi:10.1034/j.1600-0404.2002.1o174.x. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. Brooks, D. J. (2003 Aug). „Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: A randomised, placebo controlled, double blind, six month study”. J Neurol Neurosurg Psychiatry. 74 (8): 1071—9. PMC 1738605 . PMID 12876237. doi:10.1136/jnnp.74.8.1071. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. Forsberg, Markus; Lehtonen, Marko; Heikkinen, Minna; Savolainen, Jouko; Järvinen, Tomi; Männistö, Pekka T. (2003 Feb). „Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat”. J Pharmacol Exp Ther. 304 (2): 498—506. PMID 12538800. doi:10.1124/jpet.102.042846. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Kaakkola S. Kaakkola, S. (2000 Jun). „Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease”. Drugs. 59 (6): 1233—50. PMID 10882160. doi:10.2165/00003495-200059060-00004. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Entacapone

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Najib J: Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. Najib, J. (2001 Jun). „Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease”. Clinical Therapeutics. 23 (6): 802—32. PMID 11440283. doi:10.1016/s0149-2918(01)80071-0. Проверите вредност парамет(а)ра за датум: |date= (помоћ); discussion 771.

[2] Chong BS, Mersfelder TL: Entacapone. Chong, Barbara S.; Mersfelder, Tracey L. (2000 Sep). „Entacapone”. Ann Pharmacother. 34 (9): 1056—65. PMID 10981253. doi:10.1345/aph.19328. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[3] Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Poewe, W. H.; Deuschl, G.; Gordin, A.; Kultalahti, E.-R.; Leinonen, M. (2002 Apr). „Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)”. Acta Neurol Scand. 105 (4): 245—55. PMID 11939936. doi:10.1034/j.1600-0404.2002.1o174.x. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[4] Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. Brooks, D. J. (2003 Aug). „Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: A randomised, placebo controlled, double blind, six month study”. J Neurol Neurosurg Psychiatry. 74 (8): 1071—9. PMC 1738605 . PMID 12876237. doi:10.1136/jnnp.74.8.1071. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[5] Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. Forsberg, Markus; Lehtonen, Marko; Heikkinen, Minna; Savolainen, Jouko; Järvinen, Tomi; Männistö, Pekka T. (2003 Feb). „Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat”. J Pharmacol Exp Ther. 304 (2): 498—506. PMID 12538800. doi:10.1124/jpet.102.042846. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[6] Kaakkola S. Kaakkola, S. (2000 Jun). „Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease”. Drugs. 59 (6): 1233—50. PMID 10882160. doi:10.2165/00003495-200059060-00004. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[7] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[8] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[9] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[10] Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[11] Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]